Stock AnalizExelixis, Inc. EXEL
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2000 · data as of November 13, 2026
Exelixis, Inc. (EXEL) is a healthcare company listed in the US with a market value of about $16.8B. In the twelve months to October 2, 2026 it had revenue of $2.5B and net income of $885M, a net margin of 35.5%.
Its overall Stock Analiz score is 4.4 out of 5 (excellent). The strongest part is value (5/5); the weakest is shareholder returns (3/5).
Key numbers: a P/E of 20.7, a price to free cash flow of 14.5, 5-year revenue growth of 19% a year, a 5-year average ROIC of 14%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 14% above the current price.
Score: 4.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Checks not passed
- Revenue growth above 10% last year
- Pays a dividend
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.5B | $2.3B | $2.2B | $1.8B | $1.6B | $1.4B | $988M | $968M | $854M | $452M | $191M |
| Net income | $885M | $783M | $521M | $208M | $182M | $231M | $112M | $321M | $690M | $154M | -$70M |
| Free cash flow | $1.2B | $876M | $672M | $293M | $335M | $347M | $179M | $514M | $382M | $144M | $209M |
| EPS (diluted) | $3.34 | $2.78 | $1.76 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | $-0.28 |
| Net margin | 35.5% | 33.7% | 24.0% | 11.3% | 11.3% | 16.1% | 11.3% | 33.2% | 80.8% | 34.1% | -36.7% |
| ROIC | — | 29.2% | 19.4% | 5.4% | 5.9% | 10.0% | 4.9% | 17.2% | 26.6% | 56.6% | -10.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $61.57, 11% below the current price; targets range from $41.00 to $78.00; the consensus rating is “Buy”; expected EPS is $3.75 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Exelixis’s P/E ratio?
About 20.7, based on the last twelve months of diluted earnings per share (forward P/E about 17.1).
Is Exelixis stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 14% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Exelixis pay a dividend?
Not currently.
Is Exelixis a good stock to buy?
We do not give buy or sell advice. Exelixis scores 4.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.